![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KAYO-1609 is the first-in-class, oral inhibitor of the retinoid pathway, which is investigated for the treatment of genetically-defined cancers. Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024.
Lead Product(s): KAYO-1609
Therapeutic Area: Oncology Product Name: KAYO-1609
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
The net funding will support the advancement of KayoThera’s development programs in diabetes and oncology. KayoThera is developing first-in-class, oral, small molecule inhibitors of the retinoid pathway.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Accelerator Life Science Partners
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 19, 2023
Details:
The net funding will support the advancement of KayoThera’s pipeline of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: NIH NIDDK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 19, 2023
Details:
KayoThera will focus its therapeutic development efforts on its lead oncology program to further advance the technology towards a product that will benefit patients with late-stage and metastatic cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Accelerator Life Science Partners
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 16, 2022